Despite the higher risk of anal cancer among HIV-infected individuals currently there are no national or international guidelines for anal dysplasia screening. We assessed acceptance and feasibility of screening for anal intraepithelial neoplasia (AIN), the rate of abnormalities, and relationship between the presence of AIN and a history of receptive anal intercourse. Eighty-two percent of HIV-patients approached during routine clinic visit agreed to participate in the study with anal Pap smear collection; 53% had abnormal cytology results and among those undergoing high-resolution anoscopy with biopsy, 55% had high-grade AIN, including 2 cases of carcinoma in situ. Anal cytology was well accepted and it was feasible to be incorporated into HIV primary care practice. Abnormal cytology was not significantly associated with history of anal intercourse (p = 0.767). The high rate of abnormal results reinforces the need for further evaluation of the role of systematic anal Pap smear screening for HIV patients.

No comments:

Mr. Condom - you're getting some help!

On YouTube, in English, Spanish, and Thai

Welcome!

IRMA (International Rectal Microbicide Advocates) is the bottom line in HIV prevention. We work to advance the research and development of safe, effective, acceptable and accessible rectal microbicides - agents that could provide protection against HIV during anal intercourse - for the women, men, and transgender individuals around the world who need options beyond latex.